These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 31248703)
1. Why Everyone (Almost) with HIV Needs to Be on Treatment: A Review of the Critical Data. Farel CE; Dennis AM Infect Dis Clin North Am; 2019 Sep; 33(3):663-679. PubMed ID: 31248703 [TBL] [Abstract][Full Text] [Related]
2. Maximizing the benefits of antiretroviral therapy for key affected populations. Grubb IR; Beckham SW; Kazatchkine M; Thomas RM; Albers ER; Cabral M; Lange J; Vella S; Kurian M; Beyrer C; J Int AIDS Soc; 2014; 17(1):19320. PubMed ID: 25043380 [TBL] [Abstract][Full Text] [Related]
3. Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question. Eholié SP; Badje A; Kouame GM; N'takpe JB; Moh R; Danel C; Anglaret X AIDS Res Ther; 2016; 13():27. PubMed ID: 27462361 [TBL] [Abstract][Full Text] [Related]
4. The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: towards elimination of HIV transmission. Kato M; Granich R; Bui DD; Tran HV; Nadol P; Jacka D; Sabin K; Suthar AB; Mesquita F; Lo YR; Williams B J Acquir Immune Defic Syndr; 2013 Aug; 63(5):e142-9. PubMed ID: 23714739 [TBL] [Abstract][Full Text] [Related]
5. Dean Street clinics-battling London's MSM HIV epidemic. Kirby T; Thornber-Dunwell M Lancet HIV; 2018 May; 5(5):e210. PubMed ID: 29739698 [No Abstract] [Full Text] [Related]
6. Assessing the Public Health impact of HIV interventions: the critical role of demographics. Dimitrov D; Kuang Y; Mâsse BR J Acquir Immune Defic Syndr; 2014 Jun; 66(2):e60-2. PubMed ID: 24828270 [No Abstract] [Full Text] [Related]
7. The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: the modeling approach. Suthar AB; Bui DD; Granich RM; Nadol P; Tran HV; Sabin K; Williams BG; Lo YR; Kato M J Acquir Immune Defic Syndr; 2014 Jun; 66(2):e62-3. PubMed ID: 24828271 [No Abstract] [Full Text] [Related]
8. Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study. Nosyk B; Zang X; Min JE; Krebs E; Lima VD; Milloy MJ; Shoveller J; Barrios R; Harrigan PR; Kerr T; Wood E; Montaner JSG Lancet HIV; 2017 Jul; 4(7):e303-e310. PubMed ID: 28366707 [TBL] [Abstract][Full Text] [Related]
9. Adherence to Early Antiretroviral Therapy: Results From HPTN 052, a Phase III, Multinational Randomized Trial of ART to Prevent HIV-1 Sexual Transmission in Serodiscordant Couples. Safren SA; Mayer KH; Ou SS; McCauley M; Grinsztejn B; Hosseinipour MC; Kumarasamy N; Gamble T; Hoffman I; Celentano D; Chen YQ; Cohen MS; J Acquir Immune Defic Syndr; 2015 Jun; 69(2):234-40. PubMed ID: 26009832 [TBL] [Abstract][Full Text] [Related]
10. Rapid Initiation of Antiretroviral Therapy after HIV Diagnosis. García-Deltoro M AIDS Rev; 2019; 21(2):55-64. PubMed ID: 31332395 [TBL] [Abstract][Full Text] [Related]
11. Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. Geffen N; Aagaard P; Corbelli GM; Meulbroek M; Peavy D; Rappoport C; Schwarze S; Collins S; HIV Med; 2015 Apr; 16 Suppl 1(0 1):10-3. PubMed ID: 25711318 [TBL] [Abstract][Full Text] [Related]
12. How have guidelines on when to start antiretroviral therapy affected survival of people living with HIV infection? Rodger AJ; Sabin CA Curr Opin HIV AIDS; 2016 Sep; 11(5):487-491. PubMed ID: 27465878 [TBL] [Abstract][Full Text] [Related]
13. Risk of HIV transmission under combined antiretroviral therapy: toward risk zero? Supervie V; Viard JP; Costagliola D; Breban R J Acquir Immune Defic Syndr; 2015 Mar; 68(3):e41-2. PubMed ID: 25469531 [No Abstract] [Full Text] [Related]